Mediocre Q4 sales for Thoratec's HeartMate LVAD
This article was originally published in Clinica
Thoratec ended last week on a negative note as its share price fell 8% to close at $9.83 on Friday (December 3), the day after the company forecast flat fourth-quarter sales of its HeartMate XVE left ventricular assist device (LVAD). Implant rates of the product for the first two months of the fourth quarter have been similar to those of the previous quarters in 2004, which ranged between 34 and 42 implants per quarter, according to Thoratec.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.